Tarsus Pharmaceuticals, Inc. (TARS)
TARS Stock Price Chart
Explore Tarsus Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze TARS price movements and trends.
TARS Company Profile
Discover essential business fundamentals and corporate details for Tarsus Pharmaceuticals, Inc. (TARS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Oct 2020
Employees
323.00
Website
https://www.tarsusrx.comCEO
Bobak R. Azamian
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
TARS Financial Timeline
Browse a chronological timeline of Tarsus Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.38.
Earnings released on 6 Aug 2025
EPS came in at -$0.48 falling short of the estimated -$0.33 by -45.45%, while revenue for the quarter reached $102.66M , missing expectations by -9.19%.
Earnings released on 1 May 2025
EPS came in at -$0.64 surpassing the estimated -$0.69 by +7.25%, while revenue for the quarter reached $78.34M , missing expectations by -20.97%.
Earnings released on 25 Feb 2025
EPS came in at -$0.60 surpassing the estimated -$0.68 by +11.76%, while revenue for the quarter reached $66.41M , beating expectations by +3.04%.
Earnings released on 13 Nov 2024
EPS came in at -$0.61 surpassing the estimated -$0.94 by +35.09%, while revenue for the quarter reached $48.12M , beating expectations by +11.43%.
Earnings released on 8 Aug 2024
EPS came in at -$0.88 surpassing the estimated -$0.98 by +10.20%, while revenue for the quarter reached $40.81M , beating expectations by +28.91%.
Earnings released on 8 May 2024
EPS came in at -$1.01 surpassing the estimated -$1.15 by +12.17%, while revenue for the quarter reached $27.61M , beating expectations by +58.16%.
Earnings released on 27 Feb 2024
EPS came in at -$1.31 surpassing the estimated -$1.37 by +4.38%, while revenue for the quarter reached $13.08M , beating expectations by +131.02%.
Earnings released on 9 Nov 2023
EPS came in at -$1.28 surpassing the estimated -$1.40 by +8.57%, while revenue for the quarter reached $1.87M , missing expectations by -68.50%.
Earnings released on 10 Aug 2023
EPS came in at -$1.17 falling short of the estimated -$1.08 by -8.33%, while revenue for the quarter reached $15.28M , beating expectations by +768.01%.
Earnings released on 9 May 2023
EPS came in at -$0.88 surpassing the estimated -$0.95 by +7.37%, while revenue for the quarter reached $2.50M , missing expectations by -19.87%.
Earnings released on 13 Mar 2023
EPS came in at -$0.49 surpassing the estimated -$0.97 by +49.48%, while revenue for the quarter reached $10.00M , meeting expectations.
Earnings released on 9 Nov 2022
EPS came in at -$0.84 surpassing the estimated -$0.98 by +14.29%.
Earnings released on 11 Aug 2022
EPS came in at -$0.24 surpassing the estimated -$0.65 by +63.08%, while revenue for the quarter reached $15.28M , beating expectations by +35.80%.
Earnings released on 10 May 2022
EPS came in at -$0.98 falling short of the estimated -$0.87 by -12.64%, while revenue for the quarter reached $539.00K , missing expectations by -89.63%.
Earnings released on 14 Mar 2022
EPS came in at -$0.72 surpassing the estimated -$0.77 by +6.49%, while revenue for the quarter reached $338.00K , missing expectations by -81.89%.
Earnings released on 9 Nov 2021
EPS came in at -$0.76 falling short of the estimated -$0.65 by -16.92%, while revenue for the quarter reached $1.24M , missing expectations by -76.74%.
Earnings released on 4 Aug 2021
EPS came in at $0.33 surpassing the estimated -$0.48 by +168.75%, while revenue for the quarter reached $22.02M , meeting expectations.
Earnings released on 11 May 2021
EPS came in at $0.47 surpassing the estimated -$0.64 by +173.44%, while revenue for the quarter reached $33.43M , missing expectations by -59.37%.
Earnings released on 31 Mar 2021
EPS came in at -$0.68 falling short of the estimated -$0.66 by -3.03%.
Earnings released on 25 Nov 2020
EPS came in at -$3.71 falling short of the estimated -$0.50 by -642.00%.
Earnings released on 16 Oct 2020
EPS came in at -$0.30 .
TARS Stock Performance
Access detailed TARS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.